DK2468716T3 - Fremgangsmåde til fremstilling af bendamustin-alkylestere, bendamustin og derivater af samme - Google Patents
Fremgangsmåde til fremstilling af bendamustin-alkylestere, bendamustin og derivater af samme Download PDFInfo
- Publication number
- DK2468716T3 DK2468716T3 DK11009886.0T DK11009886T DK2468716T3 DK 2468716 T3 DK2468716 T3 DK 2468716T3 DK 11009886 T DK11009886 T DK 11009886T DK 2468716 T3 DK2468716 T3 DK 2468716T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- residue
- compound
- process according
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 40
- 150000002148 esters Chemical class 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 25
- -1 alkyl radical Chemical class 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 238000010931 ester hydrolysis Methods 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- 229960002707 bendamustine Drugs 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000007795 chemical reaction product Substances 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- GVLZDNWNOBSNEN-UHFFFAOYSA-N ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(=O)OCC)=NC2=C1 GVLZDNWNOBSNEN-UHFFFAOYSA-N 0.000 description 8
- SJYOJVBTSZGDQH-UHFFFAOYSA-N ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound OCCN(CCO)C1=CC=C2N(C)C(CCCC(=O)OCC)=NC2=C1 SJYOJVBTSZGDQH-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- XHMWSXLDNNNEPC-UHFFFAOYSA-N ethyl 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 XHMWSXLDNNNEPC-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XQMDIDKYVZPCNV-UHFFFAOYSA-N 4-[5-[bis(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid Chemical compound OCCN(CCO)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 XQMDIDKYVZPCNV-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- BWTJUHWTUKNKLL-UHFFFAOYSA-N ethyl 4-[4-[bis(2-hydroxyethyl)amino]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=C(N(CCO)CCO)C=C1 BWTJUHWTUKNKLL-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/46—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acids or esters thereof in presence of ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B41/00—Formation or introduction of functional groups containing oxygen
- C07B41/08—Formation or introduction of functional groups containing oxygen of carboxyl groups or salts, halides or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (18)
- FREMGANGSMÅDE TIL FREMSTILLING AF BENDAMUSTIN-ALKYLESTERE, BENDAMUSTIN OG DERIVATER AF SAMME1. Fremgangsmåde til fremstilling af en forbindelse, der er repræsenteret ved formlen (I)eller et salt deraf, hvor X står for en halogenrest, R1 og R2 er valgt således, at (1) R1 er H og R2 er CH2(CH2)mCOOR3, (2) R1 er CH2(CH2)mCOOR3 og R2 er H eller (3) R1 og R2 sammen står for en rest, som er repræsenteret ved formlen (II)hvor R3, R4 og R5 uafhængigt af hinanden står for en alkylrest, og hvor m og n uafhængigt af hinanden repræsenterer et tal i området 0 -12, kendetegnet ved, at man bringer en forbindelse, der er præsenteret ved formlen (III),til reaktion med en blanding, der er repræsenteret af en forbindelse (i), som er valgt fra gruppen, der består af en forbindelse, som er repræsenteret ved formlen (IV),hvor R6 står for H eller en alkylrest, og R7 og R8 uafhængigt af hinanden står for en alkylrest, og en forbindelse, som er repræsenteret ved formlen (V),hvor R9 og R10 uafhængigt af hinanden står for en alkylrest, består og indeholder en forbindelse (ii), som er repræsenteret ved formlen (VI).
- 2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at X repræsenterer en klorid.
- 3. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved, at R1 og R2 sammen står for en rest, der er repræsenteret ved formlen (II).
- 4. Fremgangsmåde ifølge krav 3, kendetegnet ved, at n er et heltal i området 1 - 3.
- 5. Fremgangsmåde ifølge krav 4, kendetegnet ved, at R4 står for en alkylrest, der er valgt fra gruppen, der består af en methylrest, en ethylrest og en propylrest.
- 6. Fremgangsmåde ifølge krav 5, kendetegnet ved, at R4 står for en methylrest.
- 7. Fremgangsmåde ifølge et af kravene 1 - 6, kendetegnet ved, at R5 står for en alkylrest, der er valgt fra gruppen, som består af en methylrest, en ethylrest, en propylrest og en butylrest.
- 8. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved, at R1 er H og R2 er CH2(CH2)mCOOH.
- 9. Fremgangsmåde ifølge krav 8, kendetegnet ved, at m er et heltal i området 1 -3.
- 10. Fremgangsmåde ifølge krav 9, kendetegnet ved, at m er lig med 2.
- 11. Fremgangsmåde ifølge et af kravene 1-11, kendetegnet ved, at der ved forbindelsen, som er repræsenteret ved formlen (IV), er tale om en diakylformamid.
- 12. Fremgangsmåde ifølge krav 11, kendetegnet ved, at der ved diakylformamid er tale om dimethylformamid.
- 13. Fremgangsmåde ifølge et af kravene 1-12, kendetegnet ved, at der ved forbindelsen, som er repræsenteret ved formlen (IV), er tale om dimethylacetamid.
- 14. Fremgangsmåde ifølge et af kravene 1-12, kendetegnet ved, at der ved forbindelsen, som er repræsenteret ved formlen (V), er tale om dimethylsulfoxid.
- 15. Fremgangsmåde ifølge et af kravene 1-14, kendetegnet ved, at der ved forbindelsen, som er repræsenteret ved formlen (VI), er tale om oxalylklorid.
- 16. Fremgangsmåde ifølge et af kravene 1-15, kendetegnet ved, at molforholdet mellem forbindelsen ifølge formel (VI) og forbindelsen ifølge formel (III) andrager mindst 1,3.
- 17. Fremgangsmåde ifølge et af kravene 1-16, kendetegnet ved, at reaktionen gennemføres i et kloreret opløsningsmiddel eller i et aprotisk opløsningsmiddel.
- 18. Fremgangsmåde til fremstilling af en forbindelse, som er repræsenteret ved formlen (VII),eller et salt deraf, hvor X står for en halogenrest, R11 og R12 er valgt således, at (1) R11 er H og R12 er CH2(CH2)mCOOH, (2) R11 er CH2(CH2)mCOOH og R12 er H eller (3) R11 og R12 sammen står for en rest, som er repræsenteret ved formlen (VIII),hvor R4 står for en alkylrest, og hvor m og n uafhængigt af hinanden repræsenterer et tal i området 0 - 12, kendetegnet ved, at man udfører fremgangsmåden ifølge krav 1 og udsætter den opnåede esterforbindelse, som er repræsenteret ved formlen (I), for en esterhydrolyse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426098P | 2010-12-22 | 2010-12-22 | |
| DE102010055499A DE102010055499A1 (de) | 2010-12-22 | 2010-12-22 | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2468716T3 true DK2468716T3 (da) | 2017-10-02 |
Family
ID=43993097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11009886.0T DK2468716T3 (da) | 2010-12-22 | 2011-12-15 | Fremgangsmåde til fremstilling af bendamustin-alkylestere, bendamustin og derivater af samme |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8481751B2 (da) |
| EP (1) | EP2468716B1 (da) |
| JP (1) | JP6014912B2 (da) |
| KR (2) | KR20120071339A (da) |
| CN (1) | CN102653525B (da) |
| AR (1) | AR084344A1 (da) |
| AU (1) | AU2011265491B2 (da) |
| BR (1) | BRPI1106854A2 (da) |
| CA (1) | CA2761399C (da) |
| DE (1) | DE102010055499A1 (da) |
| DK (1) | DK2468716T3 (da) |
| RU (1) | RU2505533C2 (da) |
| SG (1) | SG182090A1 (da) |
| TW (1) | TWI434835B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273010B2 (en) * | 2011-06-20 | 2016-03-01 | Hetero Research Foundation | Process for bendamustine hydrochloride |
| DK2656843T3 (da) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Estere af bendamustin og relaterede forbindelser, og medicinsk anvendelse deraf |
| US8987469B2 (en) | 2012-07-24 | 2015-03-24 | Heyl Chemisch-Pharmazeutische Fabrik Gmbh & Co. Kg | Process for the preparation of bendamustine |
| CA2890462A1 (en) | 2012-11-12 | 2014-05-15 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
| WO2023213445A1 (de) * | 2022-05-04 | 2023-11-09 | Heraeus Deutschland GmbH & Co. KG | Verfahren zur herstellung von 4-[5-[bis(2-chlorethyl)amino]-1-methyl-1h-benzo[d]imidazol-2-yl]butansäurealkylestern und formylierten derivaten |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD34727A (da) | ||||
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
| DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| GB9318691D0 (en) * | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| JP3258531B2 (ja) * | 1994-05-31 | 2002-02-18 | 三井化学株式会社 | ベンズイミダゾール誘導体 |
| DE19824929A1 (de) * | 1998-06-04 | 1999-12-09 | Basf Ag | Verfahren zur Herstellung von Alkyl-, Alkenyl- und Alkinylchloriden |
| IL149575A0 (en) * | 1999-12-08 | 2002-11-10 | Warner Lambert Co | Method for the stereoselective synthesis of cyclic amino acids |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| BRPI0409429A (pt) * | 2003-04-15 | 2006-04-18 | Pfizer | ácido carboxìlico substituìdo na posição alfa como moduladores ppar |
| US20080300401A1 (en) * | 2007-06-04 | 2008-12-04 | Polymed Therapeutics, Inc. | Novel chlorination process for preparing sucralose |
-
2010
- 2010-12-22 DE DE102010055499A patent/DE102010055499A1/de not_active Ceased
-
2011
- 2011-12-08 CA CA2761399A patent/CA2761399C/en not_active Expired - Fee Related
- 2011-12-14 SG SG2011092525A patent/SG182090A1/en unknown
- 2011-12-15 JP JP2011273992A patent/JP6014912B2/ja active Active
- 2011-12-15 EP EP11009886.0A patent/EP2468716B1/de active Active
- 2011-12-15 DK DK11009886.0T patent/DK2468716T3/da active
- 2011-12-16 AR ARP110104751A patent/AR084344A1/es active IP Right Grant
- 2011-12-20 TW TW100147538A patent/TWI434835B/zh not_active IP Right Cessation
- 2011-12-21 KR KR1020110138828A patent/KR20120071339A/ko active Search and Examination
- 2011-12-21 RU RU2011152372/04A patent/RU2505533C2/ru active
- 2011-12-22 CN CN201110463150.2A patent/CN102653525B/zh active Active
- 2011-12-22 BR BRPI1106854-0A patent/BRPI1106854A2/pt not_active IP Right Cessation
- 2011-12-22 AU AU2011265491A patent/AU2011265491B2/en active Active
- 2011-12-22 US US13/334,402 patent/US8481751B2/en active Active
-
2014
- 2014-10-14 KR KR1020140138123A patent/KR20140128926A/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011265491A1 (en) | 2012-07-12 |
| EP2468716A1 (de) | 2012-06-27 |
| JP6014912B2 (ja) | 2016-10-26 |
| TW201302714A (zh) | 2013-01-16 |
| TWI434835B (zh) | 2014-04-21 |
| JP2012131790A (ja) | 2012-07-12 |
| CA2761399C (en) | 2014-07-29 |
| US8481751B2 (en) | 2013-07-09 |
| CN102653525A (zh) | 2012-09-05 |
| US20120165543A1 (en) | 2012-06-28 |
| KR20120071339A (ko) | 2012-07-02 |
| EP2468716B1 (de) | 2017-07-19 |
| RU2505533C2 (ru) | 2014-01-27 |
| BRPI1106854A2 (pt) | 2013-04-09 |
| KR20140128926A (ko) | 2014-11-06 |
| SG182090A1 (en) | 2012-07-30 |
| AR084344A1 (es) | 2013-05-08 |
| AU2011265491B2 (en) | 2013-02-07 |
| CN102653525B (zh) | 2015-11-25 |
| CA2761399A1 (en) | 2012-06-22 |
| DE102010055499A1 (de) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2468716T3 (da) | Fremgangsmåde til fremstilling af bendamustin-alkylestere, bendamustin og derivater af samme | |
| EP3094632A1 (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation | |
| CZ305085B6 (cs) | Způsob přípravy dabigatranu | |
| JP7539451B2 (ja) | アミノピリミジン誘導体を調製するための改善されたプロセス | |
| TW200538116A (en) | Process for the preparation of substituted triazole compounds | |
| US10836730B2 (en) | Process for preparation and purification of vortioxetine hydrobromide | |
| DK169965B1 (da) | Fremgangsmåde til fremstilling af 4-substituerede indolin-2-oner, samt mellemprodukter til brug herved | |
| CZ2016627A3 (cs) | Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu | |
| JP2021119142A (ja) | キサンチンをベースとする化合物の調製方法 | |
| AU2016276573A1 (en) | Methods of making protein deacetylase inhibitors | |
| EA024409B1 (ru) | Улучшенный способ получения промежуточного соединения для синтеза рилпивирина | |
| DK175838B1 (da) | Fremgangsmåde til fremstilling af 2,6-dichlordiphenylamineddikesyrederivater | |
| US20100063292A1 (en) | Process for the preparation of trifluoroethoxytoluenes. | |
| JP2020518573A (ja) | ２−（［１，２，３］トリアゾール−２−イル）−安息香酸誘導体の製造 | |
| JP6477187B2 (ja) | ２−アミノ−６−メチルニコチン酸エステルの製造方法 | |
| KR101752449B1 (ko) | 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법 | |
| EP3424911A1 (en) | Posaconazole, composition, intermediate, preparation method therefor, and uses thereof | |
| EP1179532B1 (en) | Process for the production of indole derivatives and intermediates therefor | |
| CN114560862A (zh) | 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法 | |
| KR20080097708A (ko) | 사포그렐레이트 염산염의 제조방법 | |
| JPS6317885A (ja) | スピロピロリジン−２，５−ジオン誘導体の製造方法 | |
| JP4587139B2 (ja) | アミノアルコキシカルボスチリル誘導体の製造方法。 | |
| RU2270195C1 (ru) | Способ получения 5-амино-3-[n-ацил-n-алкиламино]-1-фенил-1,2,4-триазолов и 5-амино-3-[n-сульфонил-n-алкиламино]-1-фенил-1,2,4-триазолов | |
| SU313353A1 (ru) | Способ получения бензимидазолил-2-метилового эфира фенилдитиокарбаминовой кислоты | |
| CA1332948C (en) | Process for the preparation of substituted quinolines |